These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
81 related articles for article (PubMed ID: 2623654)
1. [Pharmacokinetics of 3'-azido-3 deoxy-thymidine (AZT) in a patient undergoing hemodialysis]. Deray G; Diquet B; Martinez F; Vidal AM; Petitclerc T; Land G; Raymond F; Baumelou A; Jacobs C Therapie; 1989; 44(6):405-8. PubMed ID: 2623654 [TBL] [Abstract][Full Text] [Related]
2. [Pharmacokinetics of zidovudine (AZT) and its metabolite (G-AZT) in healthy subjects and in patients with kidney failure]. Pioger JC; Taburet AM; Colin JN; Colaneri S; Fillastre JP; Singlas E Therapie; 1989; 44(6):401-4. PubMed ID: 2623653 [TBL] [Abstract][Full Text] [Related]
3. Influence of hemodialysis on zidovudine (AZT) and its glucuronide (GAZT) pharmacokinetics: two case reports. Garraffo R; Cassuto-Viguier E; Barillon J; Chanalet L; Lapalus P; Duplay H Int J Clin Pharmacol Ther Toxicol; 1989 Nov; 27(11):535-9. PubMed ID: 2613387 [TBL] [Abstract][Full Text] [Related]
4. Zidovudine pharmacokinetics in five HIV seronegative patients undergoing continuous ambulatory peritoneal dialysis. Kremer D; Munar MY; Kohlhepp SJ; Swan SK; Stinnett EA; Gilbert DN; Young EW; Bennett WM Pharmacotherapy; 1992; 12(1):56-60. PubMed ID: 1549540 [TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics of zidovudine and concomitant inosine-pranobex in AIDS patients. De Simone C; Ferrazzi M; Bitonti F; Falciano M; Tzantzoglou S; Delia S; Sorice F Immunopharmacol Immunotoxicol; 1988; 10(4):437-41. PubMed ID: 2469710 [TBL] [Abstract][Full Text] [Related]
6. NTP Toxicology and Carcinogenesis Studies of AZT (CAS No. 30516-87-1) and AZT/alpha-Interferon A/D B6C3F1 Mice (Gavage Studies). National Toxicology Program Natl Toxicol Program Tech Rep Ser; 1999 Feb; 469():1-361. PubMed ID: 12579204 [TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics of zidovudine in HIV-infected patients with end-stage renal disease. Kimmel PL; Lew SQ; Umana WO; Li PP; Gordon AM; Straw J Blood Purif; 1995; 13(6):340-6. PubMed ID: 8821198 [TBL] [Abstract][Full Text] [Related]
8. Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis. Knupp CA; Hak LJ; Coakley DF; Falk RJ; Wagner BE; Raasch RH; van der Horst CM; Kaul S; Barbhaiya RH; Dukes GE Clin Pharmacol Ther; 1996 Nov; 60(5):535-42. PubMed ID: 8941026 [TBL] [Abstract][Full Text] [Related]
9. [Zidovudine. The current status of its evaluation]. Kouzan S; Nebout T Therapie; 1989; 44(6):393-9. PubMed ID: 2696136 [TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics of zidovudine in a patient on maintenance hemodialysis. Deray G; Diquet B; Martinez F; Vidal AM; Petitclerc T; Ben Hmida M; Lana G; Jacobs C N Engl J Med; 1988 Dec; 319(24):1606-7. PubMed ID: 3200272 [No Abstract] [Full Text] [Related]
11. Pharmacokinetic evaluation of drug interactions with anti-human immunodeficiency virus drugs. VI. Effect of the calcium channel blocker nimodipine on zidovudine kinetics in monkeys. Gallo JM; Swagler AR; Mehta M; Qian M J Pharmacol Exp Ther; 1993 Jan; 264(1):315-20. PubMed ID: 8423534 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics of L-carnitine in patients with end-stage renal disease undergoing long-term hemodialysis. Evans AM; Faull R; Fornasini G; Lemanowicz EF; Longo A; Pace S; Nation RL Clin Pharmacol Ther; 2000 Sep; 68(3):238-49. PubMed ID: 11014405 [TBL] [Abstract][Full Text] [Related]
13. Prevalence of viremia in human immunodeficiency virus-infected patients with renal disease. Kimmel PL; VedBrat SS; Pierce PF; Umana WO; Shepherd L; Verme DA; Hirsch RP; Hellman KB Arch Intern Med; 1995 Aug 7-21; 155(15):1578-84. PubMed ID: 7618979 [TBL] [Abstract][Full Text] [Related]
14. [Pharmacokinetics of ceftriaxone in hemodialysis]. Laville M; Mercatello A; Freney J; Pozet N; Meugnier H; Labeeuw M; Fleurette J; Zech P Pathol Biol (Paris); 1987 Jun; 35(5 Pt 2):719-23. PubMed ID: 3309803 [TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics of zidovudine in end-stage renal disease: influence of haemodialysis. Pachon J; Cisneros JM; Castillo JR; Garcia-Pesquera F; Cañas E; Viciana P AIDS; 1992 Aug; 6(8):827-30. PubMed ID: 1418779 [TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic interaction of fluconazole and zidovudine in HIV-positive patients. Brockmeyer NH; Tillmann I; Mertins L; Barthel B; Goos M Eur J Med Res; 1997 Sep; 2(9):377-83. PubMed ID: 9300934 [TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of imatinib mesylate in end stage renal disease. A case study. Pappas P; Karavasilis V; Briasoulis E; Pavlidis N; Marselos M Cancer Chemother Pharmacol; 2005 Oct; 56(4):358-60. PubMed ID: 15883819 [TBL] [Abstract][Full Text] [Related]
19. [Pharmacokinetic study of zidovudine in parenteral drug addicts with human immunodeficiency virus infection]. Pachón J; Viciana P; Cisneros JM; García Pesquera F; Castillo JR; Cañas E Med Clin (Barc); 1993 Jan; 100(2):46-9. PubMed ID: 8429708 [TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and bioavailability of zidovudine in humans. Blum MR; Liao SH; Good SS; de Miranda P Am J Med; 1988 Aug; 85(2A):189-94. PubMed ID: 3165603 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]